Medivir Gets Allowance Notice From US Patent Office for Liver Cancer Treatment

MT Newswires · 2d ago
05:26 AM EDT, 07/20/2026 (MT Newswires) -- The US Patent and Trademark Office responded to Medivir's (MVIR.ST) patent application regarding the combination of fostrox and lenvatinib as a therapy for hepatocellular carcinoma and cancer metastases to the liver with a notice of allowance. The notice signals the patent authority's intention to approve the patent for the fostrox-plus-lenvatinib combination once the pharmaceutical company completes standard procedural steps, according to a Monday release. The patent - previously obtained in the European Union, Japan, Australia, and Canada - grants protection and market exclusivity until at least April 2041.